ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

Heartburn Meds May Cause Dangerous Complications for People with HIV


Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

gloved hand holding a blood sample and documenting it

Medical researchers are warning people living with HIV to be cautious about long-term use of some of the most widely taken heartburn medications in the U.S. Proton pump inhibitors (PPIs), which include Nexium, Prilosec and Prevacid among others may cause serious complications in HIV patients which can ultimately raise their risk of death.

HIV damages mucous membranes in the intestines, allowing gut bacteria to pass through the intestinal wall and find their way to other organs. These bacteria can cause inflammation in the organs where they end up. The body may respond to this inflammation with an immune activation that can increase the risk of mortality.

Infectious disease specialists at Baylor College of Medicine in Houston have found long-term PPI use may increase the amount of gut bacteria escaping to other organs, causing a “significant” increase in the risk of an immune response.

The researchers looked at 77 patients with HIV, including 37 who had been taking PPIs for an average of 3.7 years. Another 20 uninfected volunteers were also recruited for the study.

The study’s author, Dr. Jose Serpa, said the patients infected with HIV who took PPIs showed significantly higher indications of immune-system activation. Some research suggests immune activation may also be associated with cardiovascular disease in people living with HIV.

Baylor team members stopped short of saying HIV patients should quit taking PPIs, but said their findings warrant more research. They concluded that “cautious use of PPIs is advised” for people living with HIV.

The researchers published their study in Clinical Infectious Diseases.

PPIs Linked to Bacterial Overgrowth, Recurring Infections

Are you suffering from complications after taking a PPI? Get a Free Case Review

PPIs have been associated in the past with small intestinal bacterial overgrowth (SIBO), a condition in which very large amounts of bacteria grow in the small intestine. SIBO can cause chronic diarrhea and prevent the intestine from properly absorbing nutrients.

PPIs suppress the stomach’s ability to produce acid. Some research suggests this allows certain bacteria that would normally be consumed by the acid to flourish.

Previous studies have also found continuous use of PPIs may increase the risk of a serious bacterial infection called Clostridium difficile infection (C. diff.). C. diff. poses a significant risk of death and a high risk of recurring among patients who recover from it. Research has shown an association between long-term PPI use and patients developing C. diff. Other studies had indicated PPI use after an initial bout of C. diff. may increase the risks of it recurring.

Should At-Risk Patients Stop Taking PPIs?

PPIs are among the most widely prescribed medications in the U.S. — accounting for more than $10 billion in sales every year. Over-the-counter versions are also widely consumed. Studies have suggested that as much as 70 percent of the people taking PPIs do not suffer from conditions the drugs are indicated to treat. FDA guidelines say PPIs should not be taken for more than 14 days in a row, and used for no more than three, 14-day courses in a year. But they are sometimes prescribed or used outside those guidelines.

Dr. Serpa said his team’s study shows that patients should adhere to those guidelines and that it is particularly true for people living with HIV. He said their study still leaves some unanswered questions and that there is still not enough evidence to tell people to stop taking the drugs all together.

He and his fellow researchers are planning a larger study in the future to look more closely at the association between PPIs, bacterial migration from the intestines, the increased risk of inflammation and immune activation.

Terry Turner
Written By Terry Turner Writer

Terry Turner has been writing articles and producing news broadcasts for more than 25 years. He covers FDA policy, proton pump inhibitors, and medical devices such as hernia mesh, IVC filters, and hip and knee implants. An Emmy-winning journalist, he has reported on health and medical policy issues before Congress, the FDA and other federal agencies. Some of his qualifications include:

  • American Medical Writers Association (AMWA) and The Alliance of Professional Health Advocates member
  • Centers for Disease Control and Prevention Health Literacy certificates
  • Original works published or cited in Washington Examiner, MedPage Today and The New York Times
  • Appeared as an expert panelist on hernia mesh lawsuits on the BBC
Edited By

7 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Serpa, J.A., et al. (2017, July 7). Long-Term Use of Proton Pump Inhibitors Is Associated with Increased Microbial Product Translocation, Innate Immune Activation, and Reduced Immunologic Recovery in Patients with Chronic Human Immunodeficiency Virus-1 Infection. Retrieved from:
  2. Saloman, L. (2017, August 4). Proton Pump Inhibitors Present Real Risks to People Living with HIV. Retrieved from:
  3. Alcorn, K. (2017, July 13). Proton Pump Inhibitors may Blunt CD4 Cell Gains, Cause Immune Activation, in People with HIV. Retrieved from:
  4. Serpa, J.A., et al. Long-Term Use of Proton Pump Inhibitors and Increased Immune Activation in Patients with Chronic HIV-1 Infection. Retrieved from:
  5. McDonald, E.G., et al. (2015, May). Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium Difficile Infection. Retrieved from:
  6. Hughes, D. (2016, October 30). Long-Term PPI Use Discouraged for HIV-1-Infected Patients. Retrieved from:
  7. NIH. (2017, September 5). Small Bowel Bacterial Overgrowth. Retrieved from:
View All Sources
Call to speak with a legal expert
Who Am I Calling?

Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.

Drugwatch's trusted legal partners support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.

(866) 587-0279